

# Existing tools and emerging data




## WHO Danger Signs

*Seizures*  
*Intractable vomiting*  
*Lethargy*  
*Prostration*

## Gaps

Suboptimal sensitivity and specificity  
Considerable inter-observer variability




## Gaps

Hospitalised children  
Malaria endemic settings  
Focus on predicting mortality  
Biomarkers evaluated in isolation

# Spot Sepsis

Multi-country prospective cohort study

Children < 5y presenting with acute febrile illness




## Objectives

Confirm predictive performance of biomarkers (in children presenting from the community in Asia)

Develop referral tool (combining simple clinical parameters and biomarkers)

## PRESENTATION TO CARE



# Results: referral tool – development

3,423 participants recruited with 0.5% (18/3,423) loss to follow-up

133 met the primary outcome (weighted prevalence = 0.4%)

Cohort split into **derivation** (n = 2,581; events = 94) and **external geographic validation** (n = 824; events = 39)

Clinical parameters alone vs. tools containing pulse oximetry and/or biomarkers


Referral tool (clinical prediction model)	Heart rate	Respiratory rate	Temperature	Mental state	Capillary refill time	Prostration	Seizures	Intractable vomiting
Clinical	✓	✓		✓	✓	✓		✓
Clinical + SpO <sub>2</sub>	✓	✓				✓	✓	✓
Clinical + sTREM-1	✓	✓		✓		✓		✓
Clinical + CRP	✓	✓	✓	✓	✓	✓		✓
Clinical + CRP + sTREM-1	✓	✓	✓	✓		✓		✓

Tools developed using weighted logistic regression with backward stepwise selection

# Results: referral tool – clinical utility





*Remote and rural community setting*



**DISCHARGE**



**MONITOR**



**REFER**



## Results: referral tool – clinical utility

Referral tool	Disposition			Accuracy		NNT	Referrals/1000
	Discharge (%)	Monitor (%)	Refer (%)	Sensitivity (95% CI)	Specificity (95% CI)		
Clinical	90.6	8.4	1.0	<b>0.75</b> (0.62-0.87)	<b>0.99</b> (0.98-1.00)	-	10
Clinical + SpO <sub>2</sub>	94.6	5.1	0.3	<b>0.89</b> (0.80-0.97)	<b>1.00</b> (1.00-1.00)	2,300	3
Clinical + sTREM-1	90.4	7.4	2.2	<b>0.89</b> (0.80-0.97)	<b>0.98</b> (0.96-0.99)	2,300	22
Clinical + CRP	89.3	9.0	1.7	<b>0.86</b> (0.76-0.96)	<b>0.98</b> (0.97-0.99)	3,000	17
Clinical + CRP + sTREM-1	89.8	8.4	1.8	<b>0.92</b> (0.84-1.00)	<b>0.98</b> (0.97-0.99)	2,000	18

NNT = number needed to test

### Compared to WHO Danger Signs:

Sensitivity 0.56 and Specificity 0.57

NNT between 1,000 (pulse oximetry or biomarker tools) and 2,000 (clinical tool)

Referrals reduced from between 440/1,000 to between 3-22/1,000

# Results: referral tool – cost-effectiveness

## Compared to WHO Danger Signs:

All tools dominate (cost-saving and more effective)

## Compared to clinical tool:

Tool containing pulse oximetry dominates (cost-saving and more effective)

Tools containing biomarkers cost-effective: incremental cost-effectiveness ratios ~300 USD/DALY averted

## As referral costs increase:

Tool containing pulse oximetry become more advantageous due to higher specificity

Tools containing biomarkers remain cost-effective up to a referral cost of ~600 USD

Results consistent across cost-effectiveness thresholds (459-2551 USD/DALY averted)

# Conclusions

Possible to improve on existing standard of care using simple clinical parameters

Further important gains possible with pulse oximetry and biomarker testing

## Limitations

Differences between study population and intended target population (hospital vs. community)

Majority of children met the endpoint quickly\*

## Next steps

Development of quantitative point-of-care tests for biomarkers (meeting RE-ASSURED criteria)

Definitive randomised controlled and implementation trials needed

**London Calling: Recognise research as  
fundamental to MSF's social mission**



# Acknowledgements



**Eggi Arguni**



**Liz Ashley**



**Sakib Burza (PI)**



**Yoel Lubell (PI)**



**Nick Day**



**Suy Keang**



**Constantinos Kosharis**



**Bui Thanh Liem**



**Raman Mahajan**



**Dinesh Mondal**



**Rafael Perera-Salazar**



**Phan Huu Phuc**



**Michael Rekart**



**Melissa Richard-Greenblatt**



**Claudia Turner**



**Paul Turner**



**Naomi Waithira**



**Mikhael Yosia**

...and many  
many more!

Questions: [arjun@tropmedres.ac](mailto:arjun@tropmedres.ac)